Keros Therapeutics, Inc.
KROS
$18.10
$1.277.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 246.72M | 232.84M | 214.71M | 3.55M | 651.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 246.72M | 232.84M | 214.71M | 3.55M | 651.00K |
| Cost of Revenue | 157.36M | 187.07M | 184.08M | 173.63M | 165.49M |
| Gross Profit | 89.36M | 45.78M | 30.63M | -170.08M | -164.84M |
| SG&A Expenses | 45.77M | 45.46M | 40.94M | 40.75M | 39.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.13M | 232.53M | 225.02M | 214.38M | 204.69M |
| Operating Income | 43.59M | 312.00K | -10.31M | -210.83M | -204.03M |
| Income Before Tax | 71.15M | 26.89M | 14.56M | -187.05M | -181.57M |
| Income Tax Expenses | 6.70M | 8.12M | 10.34M | 300.00K | -- |
| Earnings from Continuing Operations | 64.45 | 18.77 | 4.21 | -187.35 | -181.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.45M | 18.77M | 4.21M | -187.35M | -181.57M |
| EBIT | 43.59M | 312.00K | -10.31M | -210.83M | -204.03M |
| EBITDA | 45.03M | 1.67M | -9.01M | -209.60M | -202.89M |
| EPS Basic | 1.58 | 0.35 | -0.14 | -5.01 | -5.21 |
| Normalized Basic EPS | 1.09 | 0.35 | 0.07 | -3.13 | -3.25 |
| EPS Diluted | 1.54 | 0.31 | -0.18 | -5.01 | -5.21 |
| Normalized Diluted EPS | 1.07 | 0.32 | 0.04 | -3.13 | -3.25 |
| Average Basic Shares Outstanding | 162.13M | 159.10M | 154.59M | 149.72M | 139.51M |
| Average Diluted Shares Outstanding | 162.60M | 159.56M | 155.05M | 149.72M | 139.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |